Dossier Executive Summary References
1. SEER - Surveillance Epidemiology and End-Result Program of the National Cancer Institute. Version 6.4.4. Available at: http://seer.cancer.gov/seerstat. April 24, 2008.
2. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.
3. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen-receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-34.
4. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-96.
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer, V.1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed September 11, 2008.
6. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph-node-negative, estrogen-receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82.
7. Hassett H, Pakes J, O'Malley AJ, et al. Chemotherapy-related serious adverse events and health care expenditures among commercially insured women with breast cancer. 2005 ASCO Annual Meeting; 2005.
8. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-312.
9. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph-node-negative patients. Breast Cancer Res. 2006;8(3):R25.
10. Paik S SS, Tang G. Risk classification of breast cancer patients by the recurrence score assay: comparison to guidelines based on patient age, tumor size, and tumor grade [Poster presentation]. Poster presented at the 28th Annual San Antonio Breast Cancer Symposium, December 2005; San Antonio, Texas.
11. Goldstein LJ, Gray R, Badve S, et al. Prognostic Utility of the 21-gene assay in hormone-receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26(25):4063-71.
12. Carlson RW ea. Breast Cancer. In: Clinical Practice Guidelines in Oncology: National Comprehensive Cancer Network; 2008.
13. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11(5):313-24.